Open label extension to R076477-SCH-305 to evaluate the safety and tolerability of paliperidone ER [extended release] in subjects with schizophrenia

Trial Profile

Open label extension to R076477-SCH-305 to evaluate the safety and tolerability of paliperidone ER [extended release] in subjects with schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2010

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2010 Actual patient number (407) added as reported by ClinicalTrials.gov.
    • 23 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top